Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-25 @ 2:13 AM
NCT ID:
NCT01703260
Brief Summary:
The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.
Detailed Description:
This proof of concept study will evaluate the effect of roflumilast and pioglitazone on transaminase levels and liver fat content.
Takeda has chosen not to continue this Study, however, randomized subjects were allowed to complete the study per protocol.
The decision to terminate the study is not related to any safety concerns with either of the study medications.
Study:
NCT01703260
Study Brief:
Protocol Section:
NCT01703260